Genetic Study: GLP-1 Drugs May Increase Acute Pancreatitis Risk but Not Other GI Adverse Events | Research

The takeaway

Mendelian randomization found genetically proxied GLP-1 RA use may increase acute pancreatitis risk but not other gastrointestinal adverse events.

Pancreatitis signal confirmed
Genetic evidence supports a causal link between GLP-1 receptor activation and acute pancreatitis, though the risk is specific to this condition

What the researchers found

Genetically proxied GLP-1 RA use was associated with increased acute pancreatitis risk but not other gastrointestinal adverse events in Mendelian randomization analysis.

Why it matters

The pancreatitis-GLP-1 debate has been ongoing for years. Genetic evidence suggesting a real but specific risk helps resolve this question.

How the study worked

Mendelian randomization using genetic instruments for GLP-1R activation to assess causal effects on gastrointestinal outcomes.

What this study cannot tell us

Very short abstract (370 chars). Mendelian randomization assumptions. Cannot determine risk magnitude from this data.

How to read the evidence

Mendelian randomization providing causal inference. Limited by brief abstract with minimal detail.

When this study was published

Published in 2025.

The bigger picture

Genetic evidence complementing clinical trials suggests the GLP-1-pancreatitis association may be real, even if clinical trial data has been mixed.

Questions still open

What is the absolute pancreatitis risk magnitude from genetic data?
Does the risk apply equally to all GLP-1 drugs?
Should patients with pancreatitis history avoid GLP-1 drugs?

Common questions

Do GLP-1 drugs actually cause pancreatitis?

This genetic study suggests a real causal link between GLP-1 receptor activation and acute pancreatitis — but importantly, not other stomach/GI problems that patients worry about.

Should I avoid GLP-1 drugs if I've had pancreatitis?

Patients with a history of pancreatitis should discuss this with their doctor. The genetic evidence supports a specific but real risk that may be important for predisposed individuals.

Read the original research

Association of glucagon-like peptide-1 receptor agonists with risk of gastrointestinal adverse events: evidence from a drug target Mendelian randomization.

European heart journal. Cardiovascular pharmacotherapy, 12(1), 35-37

View on PubMed ↗Publisher’s paper ↗

Citation

Huang, Haozhang; Liu, Jin; Lu, Xiaozhao; Tan, Ning; Liu, Yong. (2026). Association of glucagon-like peptide-1 receptor agonists with risk of gastrointestinal adverse events: evidence from a drug target Mendelian randomization.. European heart journal. Cardiovascular pharmacotherapy, 12(1), 35-37. https://doi.org/10.1093/ehjcvp/pvaf065